Provectus Biopharmaceuticals Inc. (NYSEMKT:PVCT) settles the shareholder lawsuit brought against the company and certain executives by Glenn Kleba and Don B. Dale. The executives have each agreed to repay to the company $2.24M of the cash bonuses they received in 2010 and 2011 which represents 70% of the amounts received or an estimate of the after-tax net proceeds received. Provectus Biopharmaceuticals Inc. (NYSEMKT:PVCT) weekly performance is 98.33%. On last trading day company shares ended up $1.19. Analysts mean target price for the company is $3.50. Provectus Biopharmaceuticals Inc. (NYSEMKT:PVCT) distance from 50-day simple moving average (SMA50) is -43.86%.
Stock analysts at R. F. Lafferty initiated coverage on shares of Zogenix Inc. (NASDAQ:ZGNX) in a report issued on Friday. The firm set a “buy” rating and a $3.50 price target on the stock. R. F. Lafferty’s target price suggests a potential upside of 90.22% from the company’s current price. Zogenix, Inc. (NASDAQ:ZGNX) shares fell -5.06% in last trading session and ended the day on $1.69. ZGNX gross Margin is 39.20% and its return on assets is -127.10%.Zogenix, Inc. (NASDAQ:ZGNX) quarterly performance is -53.95%.
Ventrus Biosciences Inc. (NASDAQ:VTUS) on May 19 has entered into a merger agreement with Assembly Pharmaceuticals, a privately held biopharmaceutical company, in an all-stock transaction. Upon the completion of the merger, the combined company will be renamed Assembly Biosciences, Inc. and trade on the Nasdaq Capital Market under the ticker “ASMB.” Once the merger is complete, the company will focus on the development of Assembly’s novel, first-in-class small molecules to treat, and potentially cure, hepatitis B virus (HBV) infection. Ventrus Biosciences Inc. (NASDAQ:VTUS) shares moved up 1.29% in last trading session and was closed at $1.57, while trading in range of $1.50 – $1.66. Ventrus Biosciences Inc. (NASDAQ:VTUS) year to date (YTD) performance is -58.90%.
Intercept Pharmaceuticals Inc. (NASDAQ:ICPT) CEO Mark Pruzanski unloaded 10,000 shares of the company’s stock in a transaction that occurred on Monday, June 2nd. The shares were sold at an average price of $230.60, for a total value of $2,306,000.00. Following the completion of the transaction, the chief executive officer now directly owns 470,174 shares of the company’s stock, valued at approximately $108,422,124. Intercept Pharmaceuticals Inc. (NASDAQ:ICPT) ended the last trading day at $278.64. Company weekly volatility is calculated as 7.17% and price to cash ratio as 43.82.Intercept Pharmaceuticals Inc. (NASDAQ:ICPT) showed a positive weekly performance of 8.95%.
KaloBios Pharmaceuticals, Inc. (NASDAQ:KBIO) announced that the company will be presenting at The 9th Annual JMP Securities Healthcare Conference on Wednesday, June 25, 2014.
KaloBios Pharmaceuticals Inc. (NASDAQ:KBIO) weekly performance is 31.18%. On last trading day company shares ended up $2.23. Analysts mean target price for the company is $7.50. KaloBios Pharmaceuticals Inc. (NASDAQ:KBIO) distance from 50-day simple moving average (SMA50) is 4.50%.